Chemotherapy-induced peripheral neuropathy common in early stage breast cancer

Share this content:

the ONA take:

Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer and was strongly associated with docetaxel-based regimens, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.

For the study, researchers from the Portuguese Institute of Oncology of Porto in Portugal sought to estimate the incidence of CIPN, identify factors associated with occurrence, and determine its impact on patient-reported outcomes.

Researchers enrolled 296 patients with incident breast cancer planning to receive chemotherapy. Patients were followed for 1 year.

Results showed that the cumulative incidence of CIPN in the first year after cancer diagnosis was 28.7% and more than 80% of participants were symptomatic 6 months after diagnosis.

The researchers found that patients who received docetaxel-based regimens were at a higher risk for developing CIPN, while alcohol consumption and diabetes were not significantly associated with CIPN.

“Symptoms persisted for at least 6 months in most patients, but severity was low and CIPN had no impact on patient-reported outcomes,” the authors conclude.

Peripheral neuropathy
Chemotherapy-induced peripheral neuropathy (CIPN) was found to be common in a cohort of patients with early stage breast cancer.
We performed a prospective cohort study including 296 patients with incident breast cancer submitted to chemotherapy, followed for 1 year. Patients with incident CIPN were reevaluated 6 months after this diagnosis. Relative risks (RR) with 95 % confidence intervals (95 % CI) were computed to quantify the relation between different clinical characteristics and the occurrence of CIPN, using Poisson regression.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs